Description: As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases
Home Page: www.editasmedicine.com
EDIT Technical Analysis
11 Hurley Street
Cambridge,
MA
02141
United States
Phone:
617 401 9000
Officers
| Name | Title |
|---|---|
| Mr. James C. Mullen | Exec. Chairman |
| Ms. Michelle Robertson | CFO, Principal Accounting Officer, Treasurer & Assistant Sec. |
| Dr. Mark S. Shearman | Exec. VP & Chief Scientific Officer |
| Dr. Bruce E. Eaton Ph.D. | Exec. VP & Chief Bus. Officer |
| Dr. Gilmore O'Neill | Pres & CEO |
| Dr. Feng Zhang Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. George McDonald Church Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. J. Keith Joung M.D., Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. David R. Liu Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Mr. Harry R. Gill III | Sr. VP of Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7176 |
| Price-to-Sales TTM: | 26.3844 |
| IPO Date: | 2016-02-03 |
| Fiscal Year End: | December |
| Full Time Employees: | 264 |